Business
Maharashtra FDA cancels Cipla Pune C&F drug-sale licence over Reactin Plus violations
Maharashtra FDA has cancelled Cipla Pharma and Life Sciences’ drug-sale and distribution licence for its Vadki, Pune C&F centre, citing stock, record-keeping, storage and packaging violations linked to Reactin Plus tablets. Cipla has challenged the order in court and says it raises no concern about the medicine’s safety, quality or efficacy.